Literature DB >> 23160200

C/EBPγ deregulation results in differentiation arrest in acute myeloid leukemia.

Meritxell Alberich-Jordà1, Bas Wouters, Martin Balastik, Clara Shapiro-Koss, Hong Zhang, Annalisa Di Ruscio, Annalisa DiRuscio, Hanna S Radomska, Alexander K Ebralidze, Giovanni Amabile, Min Ye, Junyan Zhang, Irene Lowers, Roberto Avellino, Ari Melnick, Maria E Figueroa, Peter J M Valk, Ruud Delwel, Daniel G Tenen.   

Abstract

C/EBPs are a family of transcription factors that regulate growth control and differentiation of various tissues. We found that C/EBPγ is highly upregulated in a subset of acute myeloid leukemia (AML) samples characterized by C/EBPα hypermethylation/silencing. Similarly, C/EBPγ was upregulated in murine hematopoietic stem/progenitor cells lacking C/EBPα, as C/EBPα mediates C/EBPγ suppression. Studies in myeloid cells demonstrated that CEBPG overexpression blocked neutrophilic differentiation. Further, downregulation of Cebpg in murine Cebpa-deficient stem/progenitor cells or in human CEBPA-silenced AML samples restored granulocytic differentiation. In addition, treatment of these leukemias with demethylating agents restored the C/EBPα-C/EBPγ balance and upregulated the expression of myeloid differentiation markers. Our results indicate that C/EBPγ mediates the myeloid differentiation arrest induced by C/EBPα deficiency and that targeting the C/EBPα-C/EBPγ axis rescues neutrophilic differentiation in this unique subset of AMLs.

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 23160200      PMCID： PMC3533560          DOI： 10.1172/JCI65102

Source DB:  PubMed          Journal:  J Clin Invest        ISSN： 0021-9738            Impact factor:   14.808


  80 in total

1.  Enhanced self-renewal of hematopoietic stem cells mediated by the polycomb gene product Bmi-1.

Authors:  Atsushi Iwama; Hideyuki Oguro; Masamitsu Negishi; Yuko Kato; Youhei Morita; Hiroko Tsukui; Hideo Ema; Takehiko Kamijo; Yuko Katoh-Fukui; Haruhiko Koseki; Maarten van Lohuizen; Hiromitsu Nakauchi
Journal:  Immunity       Date:  2004-12       Impact factor: 31.745

Review 2.  The role of C/EBP isoforms in the control of inflammatory and native immunity functions.

Authors:  V Poli
Journal:  J Biol Chem       Date:  1998-11-06       Impact factor: 5.157

Review 3.  Biological role of the CCAAT/enhancer-binding protein family of transcription factors.

Authors:  J Lekstrom-Himes; K G Xanthopoulos
Journal:  J Biol Chem       Date:  1998-10-30       Impact factor: 5.157

4.  Expression of a knocked-in AML1-ETO leukemia gene inhibits the establishment of normal definitive hematopoiesis and directly generates dysplastic hematopoietic progenitors.

Authors:  T Okuda; Z Cai; S Yang; N Lenny; C J Lyu; J M van Deursen; H Harada; J R Downing
Journal:  Blood       Date:  1998-05-01       Impact factor: 22.113

5.  CCAAT/enhancer binding protein epsilon is preferentially up-regulated during granulocytic differentiation and its functional versatility is determined by alternative use of promoters and differential splicing.

Authors:  R Yamanaka; G D Kim; H S Radomska; J Lekstrom-Himes; L T Smith; P Antonson; D G Tenen; K G Xanthopoulos
Journal:  Proc Natl Acad Sci U S A       Date:  1997-06-10       Impact factor: 11.205

6.  Impaired granulopoiesis, myelodysplasia, and early lethality in CCAAT/enhancer binding protein epsilon-deficient mice.

Authors:  R Yamanaka; C Barlow; J Lekstrom-Himes; L H Castilla; P P Liu; M Eckhaus; T Decker; A Wynshaw-Boris; K G Xanthopoulos
Journal:  Proc Natl Acad Sci U S A       Date:  1997-11-25       Impact factor: 11.205

Review 7.  Azacitidine for treatment of patients with myelodysplastic syndromes (MDS): practical recommendations of the German MDS Study Group.

Authors:  Katharina Götze; Uwe Platzbecker; Aristoteles Giagounidis; Detlef Haase; Michael Lübbert; Carlo Aul; Arnold Ganser; Ulrich Germing; Wolf-Karsten Hofmann
Journal:  Ann Hematol       Date:  2010-06-22       Impact factor: 3.673

Review 8.  Novel agents and regimens for acute myeloid leukemia: 2009 ASH annual meeting highlights.

Authors:  Xiongpeng Zhu; Yuehua Ma; Delong Liu
Journal:  J Hematol Oncol       Date:  2010-04-23       Impact factor: 17.388

9.  Neutrophil-specific granule deficiency results from a novel mutation with loss of function of the transcription factor CCAAT/enhancer binding protein epsilon.

Authors:  J A Lekstrom-Himes; S E Dorman; P Kopar; S M Holland; J I Gallin
Journal:  J Exp Med       Date:  1999-06-07       Impact factor: 14.307

10.  Upregulation of interleukin 6 and granulocyte colony-stimulating factor receptors by transcription factor CCAAT enhancer binding protein alpha (C/EBP alpha) is critical for granulopoiesis.

Authors:  P Zhang; A Iwama; M W Datta; G J Darlington; D C Link; D G Tenen
Journal:  J Exp Med       Date:  1998-09-21       Impact factor: 14.307
View more
  34 in total

1.  C/EBPγ suppresses senescence and inflammatory gene expression by heterodimerizing with C/EBPβ.

Authors:  Christopher J Huggins; Radek Malik; Sook Lee; Jacqueline Salotti; Sara Thomas; Nancy Martin; Octavio A Quiñones; W Gregory Alvord; Mary E Olanich; Jonathan R Keller; Peter F Johnson
Journal:  Mol Cell Biol       Date:  2013-06-17       Impact factor: 4.272

2.  EVI2B is a C/EBPα target gene required for granulocytic differentiation and functionality of hematopoietic progenitors.

Authors:  Polina Zjablovskaja; Miroslava Kardosova; Petr Danek; Pavla Angelisova; Touati Benoukraf; Alexander A Wurm; Tomas Kalina; Stephanie Sian; Martin Balastik; Ruud Delwel; Tomas Brdicka; Daniel G Tenen; Gerhard Behre; Fréderic Fiore; Bernard Malissen; Vaclav Horejsi; Meritxell Alberich-Jorda
Journal:  Cell Death Differ       Date:  2017-02-10       Impact factor: 15.828

3.  CEBPA-CEBPG axis as a novel promising therapeutic target in acute myeloid leukemia.

Authors:  Yin-jun Lou
Journal:  Acta Pharmacol Sin       Date:  2013-02       Impact factor: 6.150

4.  Progression from the Common Lymphoid Progenitor to B/Myeloid PreproB and ProB Precursors during B Lymphopoiesis Requires C/EBPα.

Authors:  Hong Guo; Theresa Barberi; Rahul Suresh; Alan D Friedman
Journal:  J Immunol       Date:  2018-07-30       Impact factor: 5.422

5.  C/EBPγ is dispensable for steady-state and emergency granulopoiesis.

Authors:  Miroslava Kardosova; Polina Zjablovskaja; Petr Danek; Pavla Angelisova; Lorena Lobo de Figueiredo-Pontes; Robert S Welner; Tomas Brdicka; Sanghoon Lee; Daniel G Tenen; Meritxell Alberich-Jorda
Journal:  Haematologica       Date:  2018-03-22       Impact factor: 9.941

6.  Identification of cancer omics commonality and difference via community fusion.

Authors:  Yifan Sun; Yu Jiang; Yang Li; Shuangge Ma
Journal:  Stat Med       Date:  2018-11-12       Impact factor: 2.373

7.  MEIS1-mediated transactivation of synaptotagmin-like 1 promotes CXCL12/CXCR4 signaling and leukemogenesis.

Authors:  Takashi Yokoyama; Mayuka Nakatake; Takeshi Kuwata; Arnaud Couzinet; Ryo Goitsuka; Shuichi Tsutsumi; Hiroyuki Aburatani; Peter J M Valk; Ruud Delwel; Takuro Nakamura
Journal:  J Clin Invest       Date:  2016-03-28       Impact factor: 14.808

8.  Proliferation and Differentiation of Murine Myeloid Precursor 32D/G-CSF-R Cells.

Authors:  Polina Zjablovskaja; Petr Danek; Miroslava Kardosova; Meritxell Alberich-Jorda
Journal:  J Vis Exp       Date:  2018-02-21       Impact factor: 1.355

9.  ZNF143 protein is an important regulator of the myeloid transcription factor C/EBPα.

Authors:  David Gonzalez; Annouck Luyten; Boris Bartholdy; Qiling Zhou; Miroslava Kardosova; Alex Ebralidze; Kenneth D Swanson; Hanna S Radomska; Pu Zhang; Susumu S Kobayashi; Robert S Welner; Elena Levantini; Ulrich Steidl; Gilbert Chong; Samuel Collombet; Min Hee Choi; Alan D Friedman; Linda M Scott; Meritxell Alberich-Jorda; Daniel G Tenen
Journal:  J Biol Chem       Date:  2017-09-12       Impact factor: 5.157

Review 10.  C/EBPα in normal and malignant myelopoiesis.

Authors:  Alan D Friedman
Journal:  Int J Hematol       Date:  2015-03-10       Impact factor: 2.490
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.